Anifrolumab More Effective Against Organ Damage Than Standard-of-Care in SLE
Patients with moderate to severe systemic lupus erythematosus treated long-term with anifrolumab may see a delay in the onset of irreversible organ damage.
Read More
Search Physician’s Weekly
Search for articles, editorials, meeting coverage, podcasts, and more
Showing 1 - 20 of 21 results for 'anifrolumab'
Anifrolumab Safe & Rapidly Effective in Refractory SLE
The following is a summary of “Anifrolumab in Refractory Systemic Lupus Erythematosus: A...
Read MoreAnifrolumab for systemic lupus erythematosus with multi-refractory skin disease: A case series of 18 patients.
Skin involvement is common in systemic lupus erythematosus (SLE), but may be resistant to conventional treatment. We sought to evaluate the efficacy of anifrolumab (ANI) in refractory cutaneous manifestations of SLE.Case series...
Read More
Anifrolumab Efficacy in Lupus Nephritis: Second-Year Extension Results
The following is a summary of “Anifrolumab in lupus nephritis: results from second-year extension...
Read More
ACR: Long-Term Safety Demonstrated for Anifrolumab in Lupus
MONDAY, Nov. 21, 2022 (HealthDay News) — For patients with systemic lupus erythematosus...
Read More
Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials.
To characterise the efficacy and safety of anifrolumab in patients with systemic lupus...
Read More
Effectiveness of Anifrolumab Across Organ Domains in Patients With Moderate-to-Severe Systemic Lupus Erythematosus
SLE (systemic lupus erythematosus) is one of the chronic autoimmune diseases that affects several...
Read More
FDA OKs Anifrolumab-fnia as Systemic Lupus Erythematosus Tx
The first approved SLE treatment in over 10 years The FDA approved anifrolumab-fnia, a type 1...
Read MoreAnifrolumab Improves Response at 52 Weeks in Lupus
Rate of composite response showing reduced disease activity higher with anifrolumab versus placebo
Read MoreAdvertisement
Anifrolumab Superior to Placebo in Moderate to Severe Lupus
Compared with placebo, anifrolumab was found to demonstrate robust efficacy in patients with moderate to severe systemic lupus erythematosus (SLE), according to research presented at the 2019 American College of...
Read More
Histochemical Kidney Analysis Suggests Potential Precision Therapy for Lupus Nephritis
This study pushes the field of rheumatology closer to precision medicine and away from a one-size-fits-all approach to treatment.
Read More
Safety and efficacy of biological agents in the treatment of Systemic Lupus Erythematosus (SLE).
To determine the safety and efficacy of biological agents used in the treatment of systemic lupus...
Read More
American College of Rheumatology, Nov. 10-14
The annual meeting of the American College of Rheumatology was held this year from Nov. 10 to 14...
Read More
Litifilimab associated with reduced disease severity in patients with cutaneous lupus erythematosus
1. Litifilimab significantly decreased cutaneous lupus erythematosus (CLE) disease area and...
Read More
ACR Updates Guidelines for Peri-TJA Med Use in Rheumatic Disease
MONDAY, March 21, 2022 (HealthDay News) — In a guideline summary issued by the American...
Read MoreMedical News Forecast for November 2-8
New FDA reviews, decisions on deck; virtual meetings continue Lynne Peterson is the Senior Writer...
Read MoreDecember 2019 Briefing – Rheumatology
Here are what the editors at HealthDay consider to be the most important developments in Rheumatology for December 2019. This roundup includes the latest research news from journal articles, as well as the FDA approvals and regulatory changes that are the most likely to affect clinical practice. Machine Learning System Makes More Alerts for Med […]
Read MoreDecember 2019 Briefing – Pharmacy
Here are what the editors at HealthDay consider to be the most important developments in Pharmacy for December 2019. This roundup includes the latest research news from journal articles, as well as the FDA approvals and regulatory changes that are the most likely to affect clinical practice. Antiepileptic Drug Exposure Low in Breastfeeding Infants TUESDAY, […]
Read More
AstraZeneca succeeds in treating lupus in late-stage study
(Reuters) – AstraZeneca Plc said on Monday its experimental treatment significantly reduced...
Read More
AstraZeneca lupus drug shows promise after set-back last year
(Reuters) – AstraZeneca Plc said on Thursday its experimental drug to treat...
Read More